Rathbones Group PLC Buys 37,037 Shares of Thermo Fisher Scientific Inc. $TMO

Rathbones Group PLC grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 942,391 shares of the medical research company’s stock after purchasing an additional 37,037 shares during the quarter. Thermo Fisher Scientific makes up approximately 1.9% of Rathbones Group PLC’s investment portfolio, making the stock its 11th largest holding. Rathbones Group PLC owned approximately 0.25% of Thermo Fisher Scientific worth $457,078,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Highline Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 126.9% in the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 33 shares during the period. Capital A Wealth Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 825.0% during the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after acquiring an additional 66 shares during the period. Cloud Capital Management LLC acquired a new position in shares of Thermo Fisher Scientific in the third quarter valued at approximately $31,000. Howard Hughes Medical Institute bought a new position in shares of Thermo Fisher Scientific during the second quarter worth approximately $33,000. Finally, Elevation Wealth Partners LLC boosted its stake in Thermo Fisher Scientific by 35.1% in the 3rd quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 20 shares during the period. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Evercore reiterated an “outperform” rating and set a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Robert W. Baird set a $653.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Friday, January 9th. UBS Group reissued a “neutral” rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Finally, The Goldman Sachs Group assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, December 9th. They set a “buy” rating and a $685.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $633.68.

Thermo Fisher Scientific Stock Down 3.3%

Shares of NYSE TMO opened at $501.72 on Friday. The stock has a market capitalization of $186.38 billion, a P/E ratio of 28.28, a PEG ratio of 2.89 and a beta of 0.96. The stock’s fifty day moving average is $567.28 and its 200 day moving average is $548.67. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, topping the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.95 billion. During the same quarter in the prior year, the business posted $6.10 earnings per share. Thermo Fisher Scientific’s revenue was up 7.2% compared to the same quarter last year. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be given a dividend of $0.47 per share. The ex-dividend date is Friday, March 13th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.70%.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares of the company’s stock, valued at $11,230,982.40. This trade represents a 1.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.